Y
Yun Gong
Researcher at University of Texas MD Anderson Cancer Center
Publications - 148
Citations - 5101
Yun Gong is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Inflammatory breast cancer. The author has an hindex of 34, co-authored 143 publications receiving 4468 citations. Previous affiliations of Yun Gong include University of Texas at Austin & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer
Christos Hatzis,Lajos Pusztai,Vicente Valero,Daniel J. Booser,Laura J. Esserman,Ana Lluch,Tatiana Vidaurre,Frankie A. Holmes,Eduardo A. Souchon,Hongkun Wang,Miguel Martin,Jose M. Cotrina,Henry L. Gomez,Rebekah Hubbard,J. Ignacio Chacón,Jaime Ferrer-Lozano,Richard Dyer,Meredith Buxton,Yun Gong,Yun Wu,Nuhad K. Ibrahim,Eleni Andreopoulou,Naoto T. Ueno,Kelly K. Hunt,Wei Yang,Arlene Nazario,Angela DeMichele,Joyce O'Shaughnessy,Gabriel N. Hortobagyi,W. Fraser Symmans +29 more
TL;DR: A genomic predictor combining ER status, predicted Chemoresistance, predicted chemosensitivity, and predicted endocrine sensitivity identified patients with high probability of survival following taxane and anthracycline chemotherapy.
Journal ArticleDOI
Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors
Naoki Niikura,Jun Liu,Naoki Hayashi,Elizabeth A. Mittendorf,Yun Gong,Shana L. Palla,Yutaka Tokuda,Ana M. Gonzalez-Angulo,Gabriel N. Hortobagyi,Naoto T. Ueno +9 more
TL;DR: The data confirmed that loss of HER2-positive status in metastatic tumors can occur in patients with primary HER2 -positive breast cancer and strongly support the need for biopsies of metastatic lesions to accurately determine patient prognosis and appropriate use of targeted therapy.
Journal ArticleDOI
EGFR and KRAS mutations in lung carcinoma: Molecular testing by using cytology specimens
TL;DR: Clinical utilization of routinely prepared cytology specimens for molecular testing to detect EGFR or KRAS mutations in lung cancer is validated.
Journal ArticleDOI
Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer
Adel Tabchy,Vicente Valero,Tatiana Vidaurre,Ana Lluch,Henry L. Gomez,Miguel Martin,Yuan Qi,Luis Javier Barajas-Figueroa,Eduardo A. Souchon,Charles Coutant,Franco Doimi,Nuhad K. Ibrahim,Yun Gong,Gabriel N. Hortobagyi,Kenneth R. Hess,Fraser Symmans,Lajos Pusztai +16 more
TL;DR: The 30-gene predictor can identify patients with greater than average sensitivity to T/FAC chemotherapy but it captured molecular equivalents of clinical phenotype, which suggests that the genomic predictor may have regimen specificity.
Journal ArticleDOI
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study
Yun Gong,Kai Yan,Feng Lin,Keith Anderson,Christos Sotiriou,Fabrice Andre,Frankie A. Holmes,Vicente Valero,Daniel J. Booser,John Pippen,Svetislava J. Vukelja,Henry L. Gomez,Jaime A. Mejia,Luis J Barajas,Kenneth R. Hess,Nour Sneige,Gabriel N. Hortobagyi,Lajos Pusztai,W. Fraser Symmans +18 more
TL;DR: A new method to assign oestrogen receptor and ERBB2-receptor status to breast carcinoma based on mRNA expression measured using Affymetrix U133A gene-expression profiling is established.